| Date | Title | Description |
| 21.08.2026 | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ)
Fri, Aug 21, 2026 07:30 CET Report this content
Lund, Sweden August 21, 2026, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office i... |
| 13.08.2026 | Oculis acquires development and commercial rights to Privosegtor |
Oculis is a biopharmaceutical company focused on neuro-ophthalmology and ophthalmology. Its late-stage clinical pipeline focuses on two core product candidates. Privosegtor and Licaminlimab. Privosegtor is a novel peptoid small-molecule ca... |
| 04.08.2026 | Two Swiss biotechs clear US regulatory steps for heart and nerve therapies |
HAYA Therapeutics, founded in 2019 and headquartered at the Biopôle life sciences park in Lausanne, develops RNA-guided therapies that target long non-coding RNAs (lncRNAs), a class of regulatory molecules in the non-coding genome. Its lea... |
| 01.06.2026 | Oculis cancels plans to seek approval for OCS-1 for diabetic macular oedema |
Oculis Holding AG, a global biopharmaceutical company focused on drugs in neuro-ophthalmology and ophthalmology, announced topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials. The DIAMOND (DIAbetic Macular edema patients ON a D... |
| 21.04.2026 | Three Swiss biotechs secure regulatory and clinical milestones |
Oculis has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for Privosegtor, its drug candidate for optic neuritis, a rare neuro-ophthalmic condition. The decision follows the FDA's Breakthrough Ther... |
| 12.03.2026 | From scientific excellence to global startups: the Swiss tech ecosystem | Switzerland’s tech ecosystem in 2025 showed strong resilience and continued specialisation in deep technology, life sciences, climate innovation, and industrial AI. Startups across the country attracted €3.3 billion in funding through hundr... |
| 24.01.2026 | Swiss VC Powerhouse Vi Partners Secures New Fund, Marks 25 Years of Innovation | Swiss venture capital titan Vi Partners celebrates 25 years of market leadership. It announced a significant first close for its new CHF 150 million (approximately €161M) fund. This strategic investment vehicle targets early-stage technolog... |
| 22.01.2026 | Vi Partners marks 25 years with first close of €161M new venture fund | Vi Partners this week announced the first close of its latest venture capital fund, targeting €161 million (CHF 150 million). It coincides with Vi Partners' 25th anniversary, marking a quarter-century of continuous venture capital activity.... |
| 21.01.2026 | Vi Partners: first closing of new CHF 150 million fund completed |
Since its founding in 2001, Vi Partners – Switzerland’s longest-standing Venture Capital firm - has supported successive generations of entrepreneurs and contributed to the development of Switzerland as a leading hub for technology and hea... |
| 08.01.2026 | Significant Advances in Pharmaceutical Pipelines for Underserved Diseases |
Oculis Holding AG has announced that its drug candidate Privosegtor was granted breakthrough therapy designation by the FDA for the treatment of optic neuritis (ON), a rare neuro‑ophthalmic condition. This approval expedites the review of ... |
| 31.10.2025 | Financial success for publicly traded biotech companies |
Idorsia is a Basel-based biotech company focused on the discovery, development, and commercialization of transformative medicines – either with in-house capabilities or together with partners. Its lead candidate QUVIVIQ™ (daridorexant) is ... |
| 13.10.2025 | Clinical milestones bring startups closer to launching new therapies |
Following a positive meeting with the U.S. Food and Drug Administration (FDA), Oculis is advancing Privosegtor, a new peptoid small molecule candidate with the potential to become the first neuroprotective therapy for acute optic neuritis ... |
| 08.09.2025 | August 2025's top 10 European tech deals you need to know about | In August, European tech companies secured €3.2 billion across 189 deals, reflecting a 66 per cent drop in investment volume and 47 per cent fewer deals compared to July 2025.
Despite this month-on-month slowdown, the market showed far grea... |
| 17.08.2025 | Bending Spoons bags €500M, Click Labs acquires Evermile, and Tesla bids to enter British energy market | This week we tracked more than 40 tech funding deals worth over €1 billion, and over 10 exits, M&A transactions, rumours, and related news stories across Europe.In addition to this week's top financials, we've also indexed the most impo... |
| 04.08.2025 | Oculis upsized loan facility to access up to CHF 100 million |
The Amended Loan Agreement replaces the prior loan agreement between Oculis and Blackrock (the Lender) dated May 29, 2024. The upsized structure will provide CHF 75.0 million in borrowing capacity, which may be increased to up to CHF 100.0... |
| 14.02.2025 | Oculis raises USD 100 million |
This Offering follows the release of recent groundbreaking data from the Phase 2 ACUITY trial of OCS-05 (Privosegtor), which has the potential to be the first neuroprotective treatment in ophthalmology, in patients with acute optic neuriti... |
| 09.01.2025 | Positive developments at Swiss biotech companies |
Dedicated to combating neglected and hard-to-treat cancers, iOnctura is developing new treatments with precision oral small molecules that target cancers in novel ways. Their lead asset, Roginolisib, is an allosteric modulator of PI3Kδ wit... |
| 14.11.2024 | Shaping the future: Healthtech innovations | Healthtech companies are crucial in shaping the future of healthcare in Europe by providing innovative technologies that improve patient outcomes and healthcare system efficiency.
These solutions range from digital tools for health monitori... |
| 30.08.2024 | US and European approvals open new avenues for Swiss Biotechs |
Life Molecular Imaging (LMI), a partner of AC Immune has received Fast Track Designation for the Tau positron emission tomography (PET) diagnostic, [18F]PI-2620, from the U.S. Food and Drug Administration (FDA) in three neurodegenerative c... |
| 11.06.2024 | Biotech startups make clinical progress |
The U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application from Anaveon to conduct a Phase I/II study evaluating the safety and clinical activity of their drug candidate ANV600. As the company’s... |
| 17.04.2024 | Oculis Shines Bright with $59 Million Funding Round | Oculis, a visionary biopharmaceutical company, has secured a dazzling $59 million in an oversubscribed funding round, propelling its mission to revolutionize eye care. The company's clinical-stage pipeline, brimming with potential, includes... |
| 15.04.2024 | Oculis secures USD 59 Million in oversubscribed offering and debuts on NASDAQ Iceland main market | Oculis secures USD 59 Million in oversubscribed offering and debuts on NASDAQ Iceland main market 15.04.2024 13:55, Rita Longobardi linkedIn facebook twitter instagram youtube -->
Oculis, a pioneering ophthalmic biopharmaceutical company... |
| 12.04.2024 | Oculis raises $59 million in oversubscribed round |
Oculis is a clinical stage biopharmaceutical company purposefully driven to save sight and improve eye care with clinical-stage pipeline comprising multiple drug candidates in development for eye diseases of high unmet need. The company bo... |
| 22.12.2023 | Clinical progress for three Biotechs | |
| 10.10.2023 | Promising breakthroughs in healthcare | |
| 02.10.2023 | Leadership changes to fuel startup growth | |
| 17.07.2023 | Earlybird Health's Inaugural Impact & ESG report reveals opportunities and gaps in investor and startups' commitments | Whether you like it or not, you'll be hearing a lot about ESG (Environmental Social Governance) metrics, commitments, and actions from now to forever.
Earlybird is one of Europe's most established and active Venture capital firms published ... |
| 14.07.2023 | Nasdaq-listed Lilium raises $192 million in shares sale and matching contribution from Tencent | Following the company’s announcement of intentions to raise $250 million back in May, Munich-based eVTOL jet maker Lilium has hit the mark.
Earlier this year, Lilium historic backer Tencent pre-funded the purchase of $100 million in shares,... |
| 12.06.2023 | Oculis secures USD 40 m | |
| 30.05.2023 | Positive results for Swiss biotechs’ clinical studies | |
| 20.03.2023 | Oculis lead candidate enters Phase 3 | |
| 03.03.2023 | Oculis goes public on Nasdaq | |
| 06.02.2023 | Additional funds for Oculis’ SPAC | |
| 23.11.2022 | Oculis presents positive Phase 2 data for a second disease | |
| 03.11.2022 | Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development | /EIN News/ -- Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development Appointments support Company pipeline with major programs and readouts expected in coming years Strength... |
| 18.10.2022 | Oculis to go public via SPAC | |
| 25.08.2022 | Encouraging Phase 2 results for Oculis’ eye drops for Dry Eye Disease | |
| 02.03.2022 | Oculis Strengthens Leading Ophthalmology Pipeline by InLicensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics | Lausanne, Switzerland, and Barcelona, Spain, March 2, 2022 – Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics,... |
| 10.01.2022 | Experienced top managers join start-ups | |
| 22.10.2021 | Veta Health Apoints CEO, Walgreens Leadership Appointments, Walmart’s New VP, Other Executive Appointments | James Sutcliffe, CEO at Veta Health
Veta Health, a global provider of digital solutions for remote patient care and chronic condition monitoring appoints James Sutcliffe as Chief Executive Officer. Sutcliffe will guide the strategic directi... |
| 11.10.2021 | Closer to customers abroad | |
| 11.05.2021 | Oculis Announces Positive Data from Two Proof-of-Concept Phase 2 Trials with OCS-02, a Novel Topical TNF alpha Antagonist, in Dry Eye Disease and Acute Anterior Uveitis, Presented at ARVO 2021 | Positive Phase 2a data, presented for the first time, highlights the potential of OCS-02 to become a new treatment in moderate to severe DED and potentially the first personalized therapy in this disease.
Data also highlight the opportunity... |
| 07.05.2021 | Oculis closes US$57 million Series C financing | |
| 07.05.2021 | Oculis closes US$57 million Series C financing | The oversubscribed round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Cap... |
| 05.05.2021 | Oculis picks up $57M Series C | Oculis, a Swiss developer of ophthalmic treatments, has secured $57 million in a round led by BVCF and Hyfinity Investments, with support from Wille and VI Partners. The capital will be used in part to fund the biopharma company's clinical ... |
| 05.05.2021 | Oculis Closes US$57M Series C Financing | Oculis S.A., a Lausanne, Switzerland-based late-stage biopharmaceutical company focused on developing ophthalmic treatments to improve the sight and lives of patients, closed a US$57m Series C financing.
The round was co-led by new investor... |
| 04.05.2021 | Oculis Announces an Oversubscribed US$57 million Series C Financing | New leading international life science investors join current institutional investors with proceeds to:
Advance novel, late-stage Investigational ophthalmology drugs OCS-01 and OCS-02 and deliver the first topical drug for retinal edema.
Ex... |
| 28.10.2020 | Seasoned executives for startups | |
| 28.10.2020 | Seasoned executives for startups | As of 9 November 2020, Annett Polaszewski-Plath will take over the position of CEO at Interprefy, the leading solution provider of cloud-based Interpreting solutions for online meetings and events. Polaszewski-Plath was most recently DACH M... |
| 14.09.2020 | Strong Swiss delegation at Bio Europe | |
| 14.09.2020 | Strong Swiss delegation at Bio Europe | Bio Europe, Europe’s largest platform designed for companies in the biotech and pharma sectors to meet and forge partnerships. Last year, the event hosted more than 4’400 visitors from 61 countries and 2300 companies. Over 27’300 one-to-one... |
| 02.09.2020 | Oculis opens subsidiary in the U.S | |
| 02.09.2020 | Oculis opens subsidiary in the U.S | Oculis’ eye drops address ophthalmic diseases for both back- and front-of-the-eye to improve the sight and lives of patients worldwide. The company’s leading clinical candidates are OCS-01 developed using Oculis’ proprietary Soluble NanoPar... |
| 12.03.2020 | Swiss startups strengthen top management for the scale-up phase | More and more Swiss start-ups enter the scale-up-phase and recruit experienced managers to lead the growth. The most recent examples: |
| 12.03.2020 | Swiss startups strengthen top management for the scale-up phase | |
| 11.02.2020 | Oculis yields positive results in phase 2 study | |
| 11.02.2020 | Oculis yields positive results in phase 2 study | Oculis' topical treatments (eye drops) address ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and lives of patients worldwide. These topical treatments represent an unprecedented technical advance for ... |
| 09.10.2019 | Oculis’ product candidate enters Phase2b clinical trial | |
| 09.01.2019 | Swiss startup Oculis secures €13.8M funding to treat ophthalmic diseases | Lausanne-based clinical-stage biopharmaceutical startup Oculis has secured €13.8 million in Series B annexe funding round by led Tekla Capital Management, with participation from Nan Fung Life Sciences and existing investors. The startup ai... |
| 08.01.2019 | Swiss startup Oculis raises €13.8 million for its eye drops to treat ophthalmic diseases | Lausanne-based biopharmaceutical startup Oculis develops novel, topical treatments for major ophthalmic diseases. It has just raised €13.8 million in a Series B extension round led by Tekla Capital Management, with participation from Nan Fu... |
| 07.01.2019 | CHF15.5 million for new treatments for eye diseases | |
| 04.01.2019 | Oculis Raises CHF15.5M in Extension of Series B Financing | Oculis, a Lausanne, Switzerland-based clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments, raised a further CHF15.5m in Series B financing.
The extension round, which brought total raised to CHF... |
| 05.01.2018 | Oculis raises CHF20 million and moves to Switzerland | |
| 04.01.2018 | Oculis Raises $20.3M Series B from Novartis Venture Fund | Oculis (www.oculis.com), a clinical-stage biotechnology company focused on the development of breakthrough non-invasive topical treatment for back-of-the-eye diseases, announced it has successfully closed a Series B financing round of CHF 2... |
| 04.01.2018 | Oculis Raises CHF20M in Series B Financing | Oculis, a Lausanne, Switzerland-based clinical-stage biotechnology company focused on the development of non-invasive topical treatment for back-of-the-eye diseases, closed a Series B financing round of CHF20m ($20.3m).
The financing was le... |
